Chiesi Group, a research-oriented international biopharmaceutical group headquartered in Parma, Italy, recorded a turnover of €2.7 billion in 2022, an increase of 13.6% from 2021. The company reported that its gross operating profit (EBITDA) grew by 7% and it has a solid positive net financial position of €1,390 million, €342 million more than previous year. In a statement, the company said that the biggest share of turnover (70%) comes from treatments for respiratory disease, followed by ...